For research use only. Not for therapeutic Use.
Catharanthine ((+)-3,4-Didehydrocoronaridine) Tartrate, a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca2+ channel (VOCC). Catharanthine Tartrate has IC50s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine Tartrate lowers blood pressure (BP), heart rate (HR). Catharanthine Tartrate has anti-cancer activity[1][2].
Catharanthine ((+)-3,4-Didehydrocoronaridine; 0.5-20 mg/kg; IV; single dose) Tartrate evokes dose-dependent reductions in both BP and HR[1].
Catharanthine (40 mg/kg; ip; single dose) Tartrate with acute administration induces similar antidepressant-like activity in male and female mice at 1 h and 24 h[1].
Catharanthine (20 mg/kg; ip; for 14 consecutive days) Tartrate increases swimming time and decreases immobility time at D7 or D14 in mice[1].
| Catalog Number | R008729 |
| CAS Number | 4168-17-6 |
| Synonyms | (2R,3R)-2,3-dihydroxybutanedioic acid;methyl (1R,15R,18R)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8,16-pentaene-1-carboxylate |
| Molecular Formula | C25H30N2O8 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H24N2O2.C4H6O6/c1-3-14-10-13-11-21(20(24)25-2)18-16(8-9-23(12-13)19(14)21)15-6-4-5-7-17(15)22-18;5-1(3(7)8)2(6)4(9)10/h4-7,10,13,19,22H,3,8-9,11-12H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t13-,19+,21-;1-,2-/m01/s1 |
| InChIKey | JYBKPXVXYJDIFX-DBOHFVDDSA-N |
| SMILES | CCC1=CC2CC3(C1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC.C(C(C(=O)O)O)(C(=O)O)O |
| Reference | [1]. Jadhav A, et al. Catharanthine dilates small mesenteric arteries and decreases heart rate and cardiac contractility by inhibition of voltage-operated calcium channels on vascular smooth muscle cells and cardiomyocytes. J Pharmacol Exp Ther. 2013 Jun;345(3):383-92. [2]. Hugo R Arias, et al. (+)-Catharanthine and (-)-18-methoxycoronaridine induce antidepressant-like activity in mice by differently recruiting serotonergic and norepinephrinergic neurotransmission. Eur J Pharmacol. 2023 Jan 15:939:175454. |
